<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59775</article-id><article-id pub-id-type="doi">10.7554/eLife.59775</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-191773"><name><surname>Baliu Piqué</surname><given-names>Mariona</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9276-8839</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192522"><name><surname>van Hoeven</surname><given-names>Vera</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192523"><name><surname>Drylewicz</surname><given-names>Julia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9434-8459</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192524"><name><surname>van der Wagen</surname><given-names>Lotte E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192525"><name><surname>Janssen</surname><given-names>Anke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192526"><name><surname>Otto</surname><given-names>Sigrid A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192527"><name><surname>van Zelm</surname><given-names>Menno C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33387"><name><surname>de Boer</surname><given-names>Rob J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2130-691X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192530"><name><surname>Kuball</surname><given-names>Jürgen JHE</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-216256"><name><surname>Borghans</surname><given-names>Jose AM</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-192529"><name><surname>Tesselaar</surname><given-names>Kiki</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9847-0814</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Center for Translational Immunology</institution>, <institution>University Medical Center Utrecht</institution>, <addr-line><named-content content-type="city">Urecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff2"><institution content-type="dept">Department of Experimental Immunology</institution>, <institution>Amsterdam UMC</institution>, <addr-line><named-content content-type="city">Amsterdam</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff3"><institution content-type="dept">Center for Translational Immunology</institution>, <institution>University Medical Center Utrecht</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution content-type="dept">Department of Hematology</institution>, <institution>University Medical Center Utrecht</institution>, <addr-line><named-content content-type="city">Urecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff5"><institution content-type="dept">Department of Immunology and Pathology</institution>, <institution>Monash University and Alfred Hospital</institution>, <addr-line><named-content content-type="city">Melbourne</named-content></addr-line>, <country>Australia</country></aff><aff id="aff6"><institution content-type="dept">Theoretical Biology and Bioinformatics</institution>, <institution>Utrecht University</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff7"><institution content-type="dept">Central Laboratory for Translational Immunology</institution>, <institution>University Medical Center Utrecht</institution>, <addr-line><named-content content-type="city">Utrecht</named-content></addr-line>, <country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-104913"><name><surname>Graw</surname><given-names>Frederik</given-names></name><role>Reviewing editor</role><aff><institution>Heidelberg University</institution>, <country>Germany</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>J.A.M.Borghans@umcutrecht.nl</email> (JB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>K.Tesselaar@umcutrecht.nl</email> (KT);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>02</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e59775</elocation-id><history><date date-type="received"><day>08</day><month>06</month><year>2020</year></date><date date-type="accepted"><day>03</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Baliu Piqué et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Baliu Piqué et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59775-v1.pdf"/><abstract><p>Lymphocyte numbers need to be quite tightly regulated. It is generally assumed that lymphocyte production and lifespan increase homeostatically when lymphocyte numbers are low, and vice versa return to normal once cell numbers have normalized. This widely-accepted concept is largely based on experiments in mice, but is hardly investigated in vivo in humans. Here we quantified lymphocyte production and loss rates in vivo in patients 0.5-1 year after their autologous hematopoietic stem cell transplantation (autoHSCT). We indeed found that the production rates of most T-cell and B-cell subsets in autoHSCT-patients were 2 to 8-times higher than in healthy controls, but went hand in hand with a 3 to 9-fold increase in cell loss rates. Both rates also did not normalize when cell numbers did. This shows that increased lymphocyte production and loss rates occur even long after autoHSCT and can persist in the face of apparently normal cell numbers.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>European Union  Seventh  Framework Programme</institution></institution-wrap></funding-source><award-id>FP7-PEOPLE-2012-ITN 317040-QuanTI</award-id><principal-award-recipient><name><surname>Baliu Piqué</surname><given-names>Mariona</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009425</institution-id><institution>Landsteiner Foundation for Blood Transfusion Research</institution></institution-wrap></funding-source><award-id>LSBR grant 0812</award-id><principal-award-recipient><name><surname>van Hoeven</surname><given-names>Vera</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Jürgen JHE Kuball, reports grants from Novartis, Miltenyi Biotech, and Gadeta. Is inventor on multiple patents dealing with γδ T-cell research, ligands, and isolation techniques, and is scientific co-founder and shareholder of Gadeta. (Patent number: 9546998, 9891211, 10324083, 10578609. Publication number: 20200368278, 20200363397, 20190271688, 2019020961, 201901692603, 20180188234, 20170319674, 20170174741, 20150050670)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was approved by the medical ethical committee of the University Medical CenterUtrecht and conducted in accordance with the Helsinki Declaration. Six patients who received an autoHSCT for the treatment of a hematologic malignancy were enrolled in the study after having provided written informed consent</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data analysed during this study are included in the manuscript  Source data is added as separate files for Figure 2, 3, 4, 6,7  and 8.</p></sec><supplementary-material><ext-link xlink:href="elife-59775-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>